T. Rowe Price Associates’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

T. Rowe Price Associates’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-911,191	Closed	-$25.1M	–	3020
2021 Q2	$25.1M	Sell	911,191 -895,254	-50%	-$17.6M	﹤0.01%	1244
2021 Q1	$29.8M	Sell	1,806,445 -162,486	-8%	-$3.7M	﹤0.01%	1172
2020 Q4	$36.3M	Buy	1,968,931 +139,636	+8%	+$2.5M	﹤0.01%	1057
2020 Q3	$24.9M	Sell	1,829,295 -113,078	-6%	-$1.74M	﹤0.01%	1090
2020 Q2	$34.8M	Buy	1,942,373 +1,785,309	+1,137%	+$26.9M	﹤0.01%	974
2020 Q1	$1.57M	Sell	157,064 -13,145	-8%	-$108K	﹤0.01%	1560
2019 Q4	$1.39M	Buy	+170,209	New	+$1.57M	﹤0.01%	1749

T. Rowe Price Associates's TBIO Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 911,191 shares — an estimated $25.1M sold.

T. Rowe Price Associates first reported a position in TBIO in Q4 2019 and held it in 7 quarters. The position peaked at $36.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

T. Rowe Price Associates reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
T. Rowe Price Associates sold 911,191 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $25.1M.
T. Rowe Price Associates first reported a position in Translate Bio, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
T. Rowe Price Associates's Translate Bio, Inc. Common Stock position peaked at $36.3M in Q4 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.